Growth Metrics

Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2025)

Historic Non-Current Debt for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $2.6 billion.

  • Amneal Pharmaceuticals' Non-Current Debt rose 1829.33% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 1829.33%. This contributed to the annual value of $2.2 billion for FY2024, which is 939.71% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Non-Current Debt of $2.6 billion as of Q3 2025, which was up 1829.33% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Non-Current Debt registered a high of $2.7 billion during Q1 2021, and its lowest value of $2.1 billion during Q2 2025.
  • Its 5-year average for Non-Current Debt is $2.5 billion, with a median of $2.6 billion in 2023.
  • In the last 5 years, Amneal Pharmaceuticals' Non-Current Debt crashed by 1464.34% in 2024 and then surged by 1829.33% in 2025.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Non-Current Debt stood at $2.7 billion in 2021, then dropped by 3.29% to $2.6 billion in 2022, then decreased by 7.95% to $2.4 billion in 2023, then dropped by 9.4% to $2.2 billion in 2024, then rose by 18.72% to $2.6 billion in 2025.
  • Its Non-Current Debt stands at $2.6 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.2 billion for Q1 2025.